Company: SCLXW
Filing Date: 2025-01-17
Form Type: 424B3
Source: 0000950170-25-006777
Chunk: 109

Company: Scilex Holding Co
Filing Date: 2025-01-17
Form: 424B3
Chunk 109
---
 16,815 |   |     | $    | (15,317 | ) |
| Net cash used for investing activities                   |     |                                 |  (2,480 | ) |     |      |    (163 | ) |
| Net cash (used for) proceeds from financing activities   |     |                                 | (10,948 | ) |     |      |  15,276 |   |
| Net change in cash, cash equivalents and restricted cash |     | $                               |   3,387 |   |     | $    |    (204 | ) |

Cash Flows from Operating Activities

For the nine months ended September 30, 2024, net cash proceeds from operating activities were approximately $16.8 million, attributable to our net loss of $66.3 million, offset by other non-cash reconciling items of $28.3 million related to stock-based compensation, change in fair value of debt and liability instruments, allocated expense for warrant issuance cost, depreciation and amortization and non-cash operating lease cost, gain on derivative liabilities, and changes in operating assets and liabilities that provided $54.9 million of cash.

For the nine months ended September 30, 2023, net cash used for operating activities was approximately $15.3 million, attributable to our net loss of $92.9 million, partially offset by other non-cash reconciling items of $20.3 million related to loss on derivative liabilities, stock-based compensation, change in fair value of debt and liability instruments, depreciation and amortization and non-cash operating lease cost, and changes in operating assets and liabilities that provided $57.3 million of cash.

Cash Flows from Investing Activities

For the nine months ended September 30, 2024, net cash used for investing activities was approximately $2.5 million and is primarily related to the $2.0 million purchase of Denali shares and $0.5 million related to payments of deferred consideration for the Romeg intangible asset acquisition under that certain license agreement, dated as of June 14 2022, by and between the Company and Romeg (the “Romeg License Agreement”).

For the nine months ended September 30, 2023, net cash used for investing activities was approximately $0.2 million, related to payments of deferred consideration for the Romeg intangible asset acquisition under the Romeg License Agreement.

Cash Flows from Financing Activities

For the nine months ended September 30,